Caris Life Sciences (CAI *) Stock Overview

An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. More details

CAI * fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 33.6% below our estimate of its fair value

Earnings are forecast to grow 64.15% per year

Revenue grew by 68.3% over the past year

Risk Analysis

Shares are highly illiquid

CAI * Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

2.1k

US$21.53

70.4% undervalued

stuart_roberts's Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

Caris Life Sciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Caris Life Sciences
Historical stock prices
Current Share Price	US$493.00
52 Week High	US$0
52 Week Low	US$0
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	CAI *	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how CAI * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how CAI * performed against the MX Market.

Price Volatility

Is CAI *'s price volatile compared to industry and market?
CAI * volatility
CAI * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: CAI *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine CAI *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2008	1,769	David Halbert	www.carislifesciences.com

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company’s molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment.

Caris Life Sciences, Inc. Fundamentals Summary

How do Caris Life Sciences's earnings and revenue compare to its market cap?
CAI * fundamental statistics
Market cap	Mex$102.26b
Earnings (TTM)	-Mex$11.74b
Revenue (TTM)	Mex$11.18b

9.2x

P/S Ratio

-8.7x

P/E Ratio

Is CAI * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CAI * income statement (TTM)
Revenue	US$649.06m
Cost of Revenue	US$258.46m
Gross Profit	US$390.60m
Other Expenses	US$1.07b
Earnings	-US$681.86m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

Feb 26, 2026

Earnings per share (EPS)	-2.42
Gross Margin	60.18%
Net Profit Margin	-105.05%
Debt/Equity Ratio	78.7%

How did CAI * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/02/19 11:55
End of Day Share Price	2025/12/16 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Caris Life Sciences, Inc. is covered by 11 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Catherine Ramsey Schulte	Baird
Michael Ryskin	BofA Global Research
Mark Massaro	BTIG

Caris Life Sciences, Inc.BMV:CAI * Stock Report